Using the nanoparticle approach, CpG has also improved tumor control of mouse MC38 and CT26 colon carcinomas when combined with mutant KRAS neoantigens, MC38 neoantigens Adpgk and Copg1, and CT26 neoantigens tmem87a and Slc4a3 (89). The gene discussed is KRAS; the disease is neoplasm.